Literature DB >> 19863539

Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study.

Ersi Voskaridou, Eleni Plata, Maroussa Douskou, Manousos Papadakis, Eleni-Evangelia Delaki, Dimitrios Christoulas, Evangelos Terpos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19863539     DOI： 10.1111/j.1365-2141.2009.07930.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

Review 1.  β-thalassemia intermedia: a clinical perspective.

Authors:  Khaled M Musallam; Ali T Taher; Eliezer A Rachmilewitz
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

Review 2.  Management of non-transfusion-dependent thalassemia: a practical guide.

Authors:  Ali T Taher; Maria Domenica Cappellini
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

Review 3.  Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.

Authors:  Matt Shirley; Greg L Plosker
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

4.  Management of transfusional iron overload - differential properties and efficacy of iron chelating agents.

Authors:  Janet L Kwiatkowski
Journal:  J Blood Med       Date:  2011-09-21

Review 5.  Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.

Authors:  Paolo Ricchi; Maria Marsella
Journal:  Drug Des Devel Ther       Date:  2015-12-16       Impact factor: 4.162

6.  β -thalassemia intermedia in Northern Iraq: a single center experience.

Authors:  Nasir A S Al-Allawi; Sana D Jalal; Ameen M Mohammad; Sharaza Q Omer; Raji S D Markous
Journal:  Biomed Res Int       Date:  2014-02-27       Impact factor: 3.411

7.  Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes.

Authors:  Ali T Taher; John B Porter; Antonis Kattamis; Vip Viprakasit; M Domenica Cappellini
Journal:  Drug Des Devel Ther       Date:  2016-12-15       Impact factor: 4.162

Review 8.  Thalassemia Intermedia: Chelator or Not?

Authors:  Yen-Chien Lee; Chi-Tai Yen; Yen-Ling Lee; Rong-Jane Chen
Journal:  Int J Mol Sci       Date:  2022-09-05       Impact factor: 6.208

Review 9.  Treating iron overload in patients with non-transfusion-dependent thalassemia.

Authors:  Ali T Taher; Vip Viprakasit; Khaled M Musallam; M Domenica Cappellini
Journal:  Am J Hematol       Date:  2013-03-08       Impact factor: 10.047

10.  Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.

Authors:  Ali T Taher; John B Porter; Vip Viprakasit; Antonis Kattamis; Suporn Chuncharunee; Pranee Sutcharitchan; Noppadol Siritanaratkul; Renzo Galanello; Zeynep Karakas; Tomasz Lawniczek; Dany Habr; Jacqueline Ros; Zewen Zhu; M Domenica Cappellini
Journal:  Ann Hematol       Date:  2013-06-18       Impact factor: 3.673
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.